Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A detailed review of modafinil's FDA approval history, international scheduling, labeled indications, and post-market safety actions across the US, EU, UK, Australia, and other major markets.
Read clinical reviewA physician-reviewed analysis of FDA Adverse Event Reporting System (FAERS) safety signals for Provigil (modafinil), including serious skin reactions, psychiatric events, and cardiovascular reports.
Read clinical reviewA complete timeline of Provigil (modafinil) FDA approval, label revisions, post-market safety actions, and current regulatory status for narcolepsy, OSA, and shift-work disorder.
Read clinical reviewA clinical guide to the FDA regulatory status of modafinil (Provigil), its compounding eligibility under federal law, and what prescribers should understand about 503A and 503B pathways.
Read clinical reviewA clinical comparison of how the FDA and EMA approved, labeled, and monitored modafinil (Provigil), including approved indications, label differences, post-market surveillance, and what each agency's decisions mean for prescribers today.
Read clinical reviewA detailed review of every FDA label change to Provigil (modafinil) from 2020 through 2026, including safety updates, boxed warning history, REMS status, and what clinicians and patients need to know today.
Read clinical reviewA complete guide to Provigil (modafinil) regulatory history, patent litigation, FDA labeling requirements, and post-market safety findings, with citations to primary sources.
Read clinical reviewA clinical review of the modafinil regulatory timeline, current generic market, and next-generation wakefulness-promoting agents in development or recently approved.
Read clinical review